Patients with asthma and major depressive disorder had more negative beliefs about their asthma, worse treatment adherence ...
A new medical large language model (LLM) achieved over 91% accuracy in identifying female participants diagnosed with major ...
A large Australian study showed atypical depression has distinct genetic, clinical, and treatment-response features. Read ...
The American College of Lifestyle Medicine has published a new expert consensus statement affirming evidence-based lifestyle interventions as foundational, primary, and adjunctive treatments for major ...
A massive reference book of mental health conditions known as the “bible” of psychiatry is going to change. The fifth and ...
The FDA has approved the first prescription, at-home neuromodulation therapy for individuals with major depressive disorder ...
The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under ...
This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-home neuromodulation treatment with FDA labeling applicable to treatment refractory MDD patients.
Detailed price information for Aytu Biopharma Inc (AYTU-Q) from The Globe and Mail including charting and trades.
ScienceAlert on MSN
Several psychiatric disorders share the same root cause, study suggests
Researchers have discovered that eight different psychiatric conditions share a common genetic basis. A study published in ...
Detailed price information for Brainsway Ltd ADR (BWAY-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results